Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 7/20 | 0.60 |
| ▸ | GRPR | P30550 | 2/20 | 0.60 |
| ▸ | NPBWR1 | P48145 | 7/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | GLP1R | P43220 | 1/20 | 0.52 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | GIPR | P48546 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433263 | 0.95 | NPBWR1 (0.65) | IL23RGRPRNPBWR1CXCR4 | |
| SCHEMBL31433319 | 0.90 | IL23R (0.52) | IL23RGRPRNPBWR1 | |
| SCHEMBL31433230 | 0.90 | NPBWR1 (0.69) | IL23RNPBWR1 | |
| SCHEMBL31433306 | 0.90 | NPBWR1 (0.69) | IL23RNPBWR1 | |
| SCHEMBL31433264 | 0.89 | CXCR4 (0.58) | IL23RCXCR4GLP1RGCGR | |
| SCHEMBL31433441 | 0.89 | CXCR4 (0.58) | IL23RCXCR4GLP1RGCGR | |
| SCHEMBL31433250 | 0.89 | CTSL (0.60) | IL23RCXCR4GLP1RGCGR | |
| SCHEMBL30811926 | 0.88 | NPBWR1 (0.61) | IL23RNPBWR1RXFP1CXCR4GLP1R | |
| SCHEMBL30598170 | 0.88 | NPBWR1 (0.61) | IL23RNPBWR1RXFP1 | |
| SCHEMBL31433169 | 0.87 | IL23R (0.66) | IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | IL23R 710/4885GRPR 564/4885NPBWR1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.